In healthy endothelium, agonistinduced eNOS activation results in transient, calcium-dependent NO production.
nNOS and eNOS are constitutively expressed and require increased intracellular Ca 2+ ([Ca 2+ ] i ) for activation whereas iNOS expression is induced in response to inflammatory stimuli and once synthesized, is tightly bound to Ca 2+ -calmodulin and is thereby constitutively active (1) (2) (3) . The primary source of NO in the vasculature is eNOS under normal conditions, whereas iNOS becomes prominent under inflammatory conditions.
Nitric oxide can exert either beneficial or pathological effects on the cardiovascular system, dictated by the amount of NO produced, subcellular localization and protein interactions of NOS, in addition to the redox state of the cellular environment (4, 5) .
Under physiological conditions, eNOS generates low levels of NO for maintenance of vascular homeostasis (6) and alterations in NO production contribute to the pathogenesis of vascular disorders such as hypertension, diabetes, heart failure and atherosclerosis (7) .
Many vascular diseases are accompanied by inflammation, resulting in a general increase in NO production which, under conditions of oxidative stress, can lead to generation of peroxynitrite and protein nitration, DNA damage and apoptosis (8, 9) . Moreover, it is generally held that vascular inflammation leads to reduced bioavailability of eNOS-derived NO and eNOS "uncoupling", accompanied by induction of endothelial iNOS expression, which is the source of high, uncontrolled NO that further exacerbates the disease process (10) . However, we have found that iNOS activity in inflamed human endothelium can be increased 3-to 5-fold beyond its basal level by G protein-coupled receptor (GPCR) signaling (11) (12) (13) and accumulating evidence indicates that eNOS could also play an "iNOS"-type role in inflammation, but the mechanisms have not been defined (14) .
The kallikrein-kinin system plays a prominent role in vascular inflammation and its biological effects are mediated by release of kinin peptides that activate two different G protein-coupled receptors named B1 (B1R), whose expression is induced by inflammatory mediators, and B2 (B2R), which is constitutively expressed (15, 16) . The B2R is selectively activated by bradykinin (BK) or kallidin (KD; Lys-BK) which can be further processed by plasma carboxypeptidase N (CPN) or membrane carboxypeptidase M (CPM) to generate des-Arg 9 -BK or des-Arg 10 -KD which no longer activate the B2R, but instead are specific B1R agonists (16) (17) (18) . Stimulation of the B2R or B1R differentially activates eNOS or iNOS respectively (19) . In healthy endothelium, the kinin B2 receptor activates eNOS resulting in a short burst of Ca 2+ -dependent NO production (20, 21) . Under inflammatory conditions, endothelial B1R stimulation leads to acute activation of iNOS via ERK1/2-dependent phosphorylation at Ser 745 and prolonged and high output NO production (11) (12) (13) . However, signaling pathways for endothelial B2R-dependent NO production under inflammatory conditions have not been investigated.
Increased Ca 2+ -calmodulin binding is a major mechanism for eNOS activation, but several other post-translational modifications govern its activity, including lipid attachment, phosphorylation, and S-nitrosylation (22, 23 (27) (28) (29) . In the present study, we discovered that B2R stimulation in cytokine-treated human lung microvascular endothelial cells (HLMVEC) induced prolonged high output NO by activating eNOS. Similar to iNOS, we found that eNOS binds calcium-calmodulin at basal Ca 2+ levels in cytokine-treated endothelial cells, enhancing its basal activity and priming it for activation independent of increased [Ca 2+ ] i . While BKinduced Ca 2+ mobilization is critical for eNOS activation in healthy endothelium, we found that BK stimulates a novel Gα i/o -mediated and MEK1/2 JNK1/2-dependent activation of eNOS in inflamed endothelium. Moreover, we established that prolonged B2R-mediated NO production reduced endothelial cell migration, a response opposite to that generated by B2R activation and NO production in control endothelial cells. were from Calbiochem/ EMD Millipore (Billerica, MA). MEK1/2 inhibitors CI-1040 (PD184352) and PD98059 were from Selleck Chemical (Houston, TX) and Cell Signaling Technology (Danvers, MA), respectively. Pertussis toxin was from List Biological Laboratories (Campbell, CA). Antibodies to human eNOS, eNOS(pThr495), eNOS(pSer633) and nNOS were from BD Transduction Laboratories (San Jose, CA), rabbit anti-iNOS (H-174) was from Santa Cruz Biotechnology (Santa Cruz, CA) and bovine eNOS(pSer617) and eNOS(pSer116) were from Upstate Cell Signaling Solutions (Lake Placid, NY). Antibodies to human eNOS(pSer1177), total-SAPK/JNK, phospho-SAPK/JNK (T183/Y185), p44/42 MAPK, phospho-p44/42 MAPK (T202/Y204), total-MEK1/2 and phospho-MEK1/2 (S217/S221) were from Cell Signaling Technology (Danvers, MA). Rabbit polyclonal antibodies to Gα i1,2 and anti-Gα q/11 were from Sigma-Aldrich (St. Louis, MO) and anti-β-actin and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were from Ambion/ Life Technologies (Grand Island, NY). Mouse monoclonal anti-calmodulin antibody (05-173) was purchased from Millipore (Temecula, CA).
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection-Human lung microvascular endothelial cells (HLMVEC) from Clonetics were used from passage 4-6 and were cultured in dishes pre-coated with 0.1% (v/v) gelatin using endothelial cell basal medium-2 supplemented with growth factors from EGM-2 MV Bullet kit (Lonza; Walkersville, MD), 10% (v/v) fetal bovine serum (FBS), and 1% (v/v) penicillin-streptomycin solution (Cellgro; Manassas, VA).
Human embryonic kidney (HEK293) cells from ATCC (Manassas, VA) were cultured in low glucose Dulbecco's Modified Eagle Medium (DMEM) (GIBCO/ Life Technologies; Grand Island, NY) supplemented with 10% (v/v) FBS and 1% (v/v) penicillinstreptomycin solution.
HEK293 cells were transiently transfected using Effectene (Qiagen; Valencia, CA) reagent according to the manufacturer's instructions. Unless otherwise indicated, all experiments using HLMVEC or HEK293 cells were performed in phenol-red-free DMEM Nutrient Mix F-12 (Ham) from GIBCO/ Life Technologies (Grand Island, NY), supplemented with 0.5% (v/v) FBS.
Cytokine treatment-HLMVEC or HEK293 cells were treated with 5 ng/ml interleukin-1β (IL-1β) (Calbiochem/ EMD Millipore; Billerica, MA) and 100 U/ml interferon-γ (IFN-γ) (Invitrogen/ Life Technologies; Grand Island, NY) for 16-24 h to stimulate inflammation. Because cytokine treatment induces expression of kinin B1 receptors (B1R) and carboxypeptidase M (CPM), which can convert BK to the B1R agonist des-Arg 9 -BK, cells were routinely pretreated with B1R antagonist DALKD (1 μM) and CPM inhibitor MGTA (20 μM) for 30 min to block the B1R pathway, unless otherwise indicated.
RNA Interference-Small interfering RNA (siRNA) from Sigma-Aldrich (St. Louis, MO) was synthesized using previously published and validated sequences for eNOS (30), MEK1 (31), MEK2 (31), and JNK1/2 (32). Sequences (sense) are as follows: eNOS 5-′GGUCUGCACA-
was from Santa Cruz Biotechnology and used as a negative control. HLMVEC were electroporated with 100 nM siRNA using the Amaxa Biosystems Nucleofector system (Lonza; Walkersville, MD) based on the manufacturer's kit and protocol (S005) optimized for HLMVEC. Cells were treated with cytokines 48-72 h later. Approximately 72-96 h post-transfection, total cell lysates were collected and protein knockdown efficiency was assessed by Western blot analysis.
Western Blotting-HLMVEC were washed once with ice-cold phosphate buffered saline (PBS) containing 1 mM Na 3 VO 4 . Cells were then lysed in ice-cold 2x Laemmli buffer (0.125 M Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.004% (w/v) bromophenol blue) supplemented with fresh 3% (v/v) β-mercaptoethanol, 1 mM Na 3 VO 4 , 20 mM β-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1% (v/v) protease inhibitor solution (Sigma-Aldrich; St. Louis, MO) . HEK293 cells were washed once with ice-cold PBS containing 1 mM Na 3 VO 4 and lysed with icecold buffer containing 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 0.1% (w/v) SDS and 0.5% (w/v) sodium deoxycholate supplemented with fresh 3% (v/v) β-mercaptoethanol and inhibitors as stated above. Cells were lysed on ice for 30 min, collected and centrifuged at 14,000 x g for 15 min at 4 o C. Cell lysates were separated on 10% SDS-PAGE gels and electrophoretically transferred to Immobilon PVDF membranes (EMD Millipore; Billerica, MA). Blots were blocked with 5% (w/v) evaporated nonfat milk in PBS containing 0.1% (v/v) Tween-20 and then incubated with the appropriate primary antibodies followed by horseradish peroxidase-labeled secondary antibody and the bands were visualized by enhanced chemiluminescence (Pierce/ Thermo Scientific; Rockford, IL).
Co-immunoprecipitation Assay-Control and cytokine-treated HLMVEC (~2.5x10 6 cells per condition; not stimulated with BK) were washed once with ice-cold PBS containing 1 mM Na 3 VO 4 and lysed with ice-cold buffer (500 μl) containing 25 mM HEPES (pH 7.7), 0.3 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1% (v/v) Triton X-100, supplemented with fresh 1 mM dithiothreitol (DTT), 1 mM Na 3 VO 4 , 20 mM β-glycerophosphate, 1 mM PMSF and 1% (v/v) protease inhibitor solution. Lysates were collected and centrifuged at 14,000 x g for 10 min at 4 o C. eNOS was precipitated from the supernatant by rotating at 4 o C with 6 μg of rabbit anti-eNOS antibody for 12-16 h followed by pull down with protein G Sepharose beads Sigma-Aldrich (St. Louis, MO) that were added 2 h before the end of the incubation period. Samples were resolved on a 4-20% mini-PROTEAN® TGX TM precast gel (Bio-Rad; Richmond, CA) and calmodulin was detected by immunoblotting with mouse anticalmodulin antibody.
NO measurements-Cells were incubated in phenol-red-free DMEM/F-12 supplemented with 0.5% (v/v) FBS containing 1 μM DALKD and 20 μM MGTA for 30 min prior to addition of 100 nM BK or 100 nM BK-analog. Basal NOS activation was accessed by incubating cells in L-Arg-free DMEM/F-12 medium (without FBS) for 2 h prior to stimulation with 1 mM L-Arg. To directly measure NO production in real time, a highly sensitive porphyrinic microsensor was positioned with a micromanipulator close to the cell culture surface (20 ± 1μm) and used as previously described (21,33). A computer-based Gamry VP600 potentiostat was used to measure the current generated, which was proportional to the NO released. Each electrode used was calibrated with NO standard. Wound healing assay-Wound healing was assessed using the in vitro scratch assay technique as previously described (35). Briefly, a cell-free zone, within a confluent monolayer of control or cytokine-treated HLMVEC, was formed down the center of a 6-well tissue-culture dish by removing cells with the pointed end of a sterile 200 μl pipette tip. Cells were then washed 2x with serum-free media and sustained in growth factorfree EBM-2 medium supplemented with 10% (v/v) FBS, 1 μM DALKD, 20 μM MGTA, without or with 10 μM HOE-140, 4 μM L-NNA or 10 µM tempol. Using phase contrast microscopy, 5-10 distinct images of unstimulated cells along the cell-free zone were taken and the coordinates were documented. Thereafter, cells were stimulated with 1 μM BK or 15 μl vehicle (basal DMEM/F-12 medium) and images were collected 12 h later at the original coordinates. Wound closure was quantified by measuring the area of the cell-free zone before and 12 h after BK-stimulation. Using Lastly, samples were analyzed with a Zeiss ApoTome microscope using an excitation wavelength in the range of 450-500 nm and detection in the range of 515-565 nm.
Modified Boyden Chamber AssayEndothelial transmigration was performed using 24-well Millicell® hanging cell culture inserts containing PET membranes with 8.0 µm pores (Millipore; Billerica, MA). Briefly, membranes were pre-coated overnight with 0.1% (v/v) gelatin and then air-dried. The bottom wells were filled with EBM-2 medium supplemented with growth factors from EGM-2 MV Bullet kit and 10% (v/v) FBS and the Millicell® cell culture insert was inserted into the top. A cell suspension (~1.0x10 5 control or cytokine-treated HLMVEC in 400 μl of EBM-2 medium supplemented with 10% (v/v) FBS) without or mixed with agonist and/or inhibitors, was added to the top chamber. Transmigration through the membrane was allowed to proceed for 8 h at 37 o C in a humidified atmosphere of 95% air and 5% CO 2 . The bottom surface of the membrane was then washed once with PBS and fixed with 4% (v/v) paraformaldehyde for 10 min at room temperature. Cells on the upper surface of the membrane were carefully removed with a cotton tip. The membranes were then excised from the insert, washed twice with H 2 O, air dried and mounted with ProLong ® Gold antifade reagent with DAPI. Cells present on the lower surface of the membrane were counted under a Zeiss ApoTome microscope.
RESULTS
Kinin B2 receptor (B2R) activation generates prolonged NO production in inflamed endothelial cells -B2R-mediated eNOS activation in bovine aortic endothelial cells and human umbilical vein endothelial cells has been well characterized (20, 26) . However, B2R-stimulated NO production has not been studied in endothelial cells under inflammatory conditions that are classically associated with activation of the kallikrein-kinin system and generation of B2R agonist kinins (15, 16) .
To investigate this, human lung microvascular endothelial cells (HLMVEC) or human embryonic kidney cells transiently expressing B2R and eNOS (HEK-B2R/eNOS) were pretreated with 5 ng/ml of interleukin-1beta (IL-1β) and 100 U/ml of interferon-gamma (IFN-γ) for 16-24 h ("cytokine treated"). Unless otherwise indicated, cells were then pre-incubated for 30 min with B1R antagonist DALKD (1 μM) and carboxypeptidase inhibitor MGTA (20 μM). This pretreatment blocks B1R signaling by antagonizing the receptor and inhibiting the carboxypeptidase-mediated conversion of bradykinin (BK) to B1R agonist des-Arg 9 -BK (17, 18, 21) . We found that stimulation of the B2R with 100 nM BK in control HLMVEC (Fig. 1A,  top) or HEK-B2R/eNOS (Fig. 1B, top) resulted in transient NO, reaching a maximum at 5 min and returning to baseline in 10 min. However, in cytokine-treated HLMVEC (Fig. 1A, top) or cytokine-treated HEK-B2R/eNOS (Fig. 1B, top) , BK induced higher and more prolonged NO, reaching a maximum in ~40 min and not returning to baseline until ~80 min.
To confirm that the prolonged NO response was mediated via B2R (and not B1R) activation, we used a pseudopeptide BK analog, [Phe
bradykinin, that has a non-peptide Cterminal bond (36). This BK analog cannot be cleaved by carboxypeptidases, thus preventing its conversion into a des-Arg 9 B1R agonist, allowing experiments to be done in the absence of DALKD and MGTA. As shown in Fig. 1C (top) , BK analog also stimulated prolonged NO production in cytokine-treated HLMVEC. The response to BK (Fig. 1A, bottom) and BK analog (Fig. 1C accumulation (after 60 min) in medium from cytokine-treated HEK-B2R/eNOS cells (64 ± 15 nM, n = 3) whereas there was no detectable increase in NO 3 -/NO 2 -in control HEK-B2R/eNOS cells stimulated with BK, suggesting an increase in eNOS-derived NO under cytokine-treated conditions. For unknown reasons, the same assay did not give reproducible results in HLMVEC, so in these cells we used a previously published approach (37) using the long half-life (20h) NO donor DETA-NONOate to test whether BK stimulation results in decreased NO consumption. DETA-NONOate provides a constant source of NO which, after a few minutes of incubation with cells, rises to a plateau (as measured with a microelectrode) whose amplitude is inversely correlated with the rate of NO consumption and varies, depending on cell type (37). Cytokinetreated HLMVEC were pre-incubated with 4 µM L-NNA and 4 µM 1400W to block eNOS and iNOS and then DETA-NONOate (5 µM) was added to the cells. NO, measured continuously with the microsensor, achieved a steady state concentration of ~260 nM after ~8 min. Addition of 100 nM BK at 10 min did not change the steady-state concentration of NO which, when measured at 20 min, was 250 ± 25 nM with NO donor alone vs. 275 ± 20 nM with NO donor + BK (n = 3), indicating that BK stimulation does not inhibit NO consumption.
One other potential mechanism by which BK might increase NO is by enhancing nitrite reductase activity to convert NO 2 -to NO, which has also been reported to be catalyzed by eNOS, although only under hypoxic and/or acidic conditions (39) . To test this, cytokine-treated HLMVEC were pre-incubated in L-Arg-free medium (as 300 µM L-Arg can inhibit eNOS nitrite reductase activity(39)) with 4 µM 1400W to block iNOS. Addition of 10 µM NO 2 -alone or 10 µM NO 2 -+ 100 nM BK did not generate significant NO after 20 min as measured with the porphyrinic microsensor (10 ± 10 nM NO or 15 ± 15 nM NO, respectively; n = 3). Thus, the BKstimulated NO response is not due to activation of nitrite reduction. It is of interest that the lack of a response in the absence of extracellular L-Arg is usually considered to be a property of iNOS regulation but not eNOS (40) .
The above data support the conclusion that the prolonged NO output stimulated by BK-mediated B2R activation in cytokine-treated cells is due to increased NOS activity.
Prolonged B2R-mediated NO production is mediated by eNOS activation -We previously reported that in cytokine-treated HLMVEC, B1R activation results in post-translational activation of iNOS leading to very high and prolonged NO production (11, 12) . Interestingly, the time-course of B2R-mediated NO production in cytokinetreated HLMVEC (Fig. 1A, top) is strikingly similar to that generated by B1R-mediated activation of iNOS (11, 12) . However, the total NO released by B2R activation (based on area under the curve for the total NO response) was ~53% of the B1R-stimulated iNOS response (11) in cytokine-treated HLMVEC (300 ± 25 area units for B1R/iNOS vs. 160 ± 20 area units for B2R-stimulated NO; n = 3). To determine which NOS isoform was being activated, we used L-NNA to inhibit eNOS and 1400W to inhibit iNOS. (Based on Ki values, L-NNA is ~100-fold more selective for eNOS/nNOS than iNOS, whereas 1400W is ~7000-fold more selective for iNOS than eNOS). Using the porphyrinic microsensor, B2R-mediated NO production was inhibited 60-80% by 4 µM L-NNA, whereas 4 µM 1400W had only a minor effect in HLMVEC (Fig. 1A , bottom) and HEK-B2R/eNOS (Fig. 1B, bottom) .
Similar results were obtained with the BK analog [Phe 8 ψ(CH 2 -NH)Arg 9 ]bradykinin in the absence of DALKD and MGTA (Fig. 1C, bottom) . NOS inhibitor selectivity was verified by stimulating receptorindependent NOS activity in human embryonic kidney (HEK) cells over-expressing either iNOS or eNOS alone. We confirmed that 4 μM L-NNA inhibited Ca 2+ ionophore (10 μM A23187) stimulated eNOS activity but not basal L-Argstimulated iNOS activity, whereas 4 μM 1400W inhibited L-Arg-stimulated iNOS activity but not A23187-stimulated eNOS activation (data not shown). When BK was used to stimulate HEK cells transfected with only the B2R (in the absence of eNOS) in both control and cytokine-treated cells, there was no NO response as detected with the porphyrinic microsensor, nor NO 3 -/NO 2 -accumulation measured with the DAN reagent (data not shown). Because L-NNA can also inhibit nNOS, we explored whether B2R stimulation might activate nNOS in cytokine-treated HLMVEC. Although nNOS is typically localized in neuronal tissue, its expression was also reported in endothelial cells (41, 42) .
First, we analyzed eNOS, iNOS and nNOS protein expression in total cell lysates collected from control and cytokinetreated HLMVEC. As shown in Fig. 2A , cytokine treatment increased expression of iNOS but did not alter eNOS or nNOS protein expression. We also measured BK-stimulated NO production from cytokine-treated HLMVEC pretreated with NOS inhibitor N w -propyl-L-arginine (0.01-10 μM) which has ~8-fold selectivity for nNOS (Ki = 5 nM) over eNOS (Ki=39 nM). As shown in Fig.  2B , substantial inhibition of B2R-mediated NO production was only seen with high concentrations of N w -propyl-L-arginine (1 -10 µM), consistent with suppression of eNOS activity.
To confirm that B2R-mediated NO production was derived from eNOS, we transfected HLMVEC with siRNA targeting human eNOS (30) followed by cytokine treatment. As shown in Fig. 2C , we achieved ~85% knockdown of eNOS expression and B2R-mediated NO production was reduced by 61% in cytokine-treated HLMVEC transfected with eNOS siRNA compared with cells transfected with non-specific control siRNA. The residual NO production was due to the remaining eNOS, as it was blocked by eNOS inhibitor (L-NNA) but not with iNOS inhibitor 1400W (Fig.  2C ). Similar inhibition of NO production was obtained when we knocked down eNOS expression in control HLMVEC and used A23187 to stimulate receptor-independent eNOS activity ( Fig. 2D) . Overall, our data show that cytokine treatment induces B2R-mediated and eNOSdependent prolonged NO production.
Cytokine treatment induces a time-dependent change in kinetics of B2R-mediated NO production-Cytokines can alter cell functions by promoting changes in gene expression and protein synthesis over a time course of several hours (43) . We previously showed that IL-1β and IFN-γ increased expression of CPM, B1R and iNOS in HLMVEC (21,44). To determine if prolonged B2R-mediated NO production was acutely affected by cytokine treatment or required a prolonged incubation, we measured the kinetics of NO production in HLMVEC treated with IL-1β and IFN-γ for 2, 6, 10 or 16 h prior to stimulation with 100 nM BK. As shown in Fig. 3 , the kinetic profile of B2R-mediated NO production did not differ from untreated cells at 2 h, but noticeably changed 6 h post-cytokine treatment, resulting in two phases of NO production. The first peak is similar to that observed in untreated cells, reaching maximal NO levels in 5 min, but instead of returning to baseline, the initial rapid peak is superimposed on a slower developing second phase of NO production. Pretreatment with cytokines for 10 h or 16 h prior to BK stimulation almost eliminated the initial transient peak while leaving the prolonged phase intact.
Divergent G protein-coupled signaling pathways mediate B2R-dependent eNOS activation in control and cytokine-treated HLMVEC-
The kinin B2R is a prototypical Gα q/11 -coupled receptor whose activation leads to stimulation of phospholipase C (PLC) and increased [Ca 2+ ] i , but it can also couple through Gα i/o (16, 45) . To determine whether Gα q/11 -mediated Ca 2+ release was required for B2R-mediated eNOS activation, we measured NO production from control and cytokine-treated HLMVEC (Fig. 4A ) and HEK-B2R/eNOS (Fig. 4B ) pretreated with the [Ca 2+ ] i chelator BAPTA-AM (25 μM) for 30 min. In control cells, B2R-mediated NO production was reduced by BAPTA-AM, consistent with a Gα q/11 -coupled response. In contrast, prolonged B2R-mediated NO production in cytokine-treated cells was not inhibited by 25 μM BAPTA-AM using either BK (Fig. 4A) 4C) as agonist. However, the remaining small initial transient peak was blocked (Fig. 5A) , indicating it is a remnant of the B2R response found in control HLMVEC as indicated in Fig. 3 . A higher concentration of BAPTA-AM (37.5 μM) was also ineffective in inhibiting prolonged B2R -mediated NO production in cytokine-treated HLMVEC (data not shown), and the response was unaffected by pretreatment with thapsigargin (2 μM) to deplete [Ca 2+ ] i stores or a combination of BAPTA-AM and thapsigargin (Fig. 5B) . Furthermore, the prolonged B2R-mediated response in cytokine-treated HLMVEC was still present in cells that were pre-incubated in Ca 2+ -free media in the absence or presence of 2-aminoethoxydiphenyl borate (2-ABP; 50 μM) to block the IP 3 receptor (Fig. 5C) (Fig. 5E) . Thus, the lack of Ca 2+ -dependence of the eNOS response to BK in cytokine-treated HLMVEC is not due to the inability of BK to stimulate increased [Ca 2+ ] i . To determine if the prolonged B2R-mediated NO response in cytokine-treated cells was dependent on coupling through Gα i/o , we measured NO production from control and cytokine-treated HLMVEC pretreated with 1.5 μg/ml pertussis toxin (PTx) for 3 h prior to stimulation with BK. As shown in Fig. 4A & 4B , PTx had no effect on B2R-mediated NO production in control HLMVEC or HEK-B2R/eNOS, but substantially inhibited the response in cytokine-treated cells, indicating that it is mediated by B2R coupling through Gα i/o . PTx also inhibited the prolonged B2R-dependent NO stimulated by
Because PI3K-mediated Akt activation is involved in the regulation of eNOS by many agonists, we measured the effect of Akt inhibitor SH-6 on B2R-mediated NO production from control and cytokine-treated HLMVEC (Fig. 4A) or HEK-B2R/eNOS (Fig. 4B ). SH-6 (15 μM) significantly reduced B2R-mediated NO generation in control cells, but had no effect on cytokine-treated HEK-B2R/eNOS cells, and inhibited only ~20% of the response in cytokinetreated HLMVEC. To further study the possible role of Akt in HLMVEC, we treated cells with a different highly specific and potent allosteric Akt inhibitor, MK2206 (5 µM) and found, as with SH-6, that it inhibited B2R-mediated NO generation in control cells, but this inhibitor had no effect in cytokine-treated HLMVEC (Fig. 4A ), even at higher concentrations up to 50 µM (not shown). Thus, the B2R-mediated NO response in cytokinetreated HLMVEC is independent of Akt activation.
Effect of cytokine treatment on Ca 2+ -CaM binding and basal eNOS activity -Both eNOS and nNOS typically require an increase in intracellular Ca 2+ for activation, whereas iNOS binds Ca 2+ -CaM tightly at low basal Ca 2+ levels and is therefore constitutively active (1-3). To determine if cytokine treatment enhances basal eNOS affinity for Ca 2+ -CaM, we immunoprecipitated total eNOS from control and cytokine-treated HLMVEC and immunoblotted for co-immunoprecipitated CaM. Interestingly, there was a ~4-fold increase in Ca 2+ -CaM association with eNOS in cytokine-treated cells compared with control cells (Fig. 6A) . Total cell lysates collected from control and cytokinetreated HLMVEC indicated no difference in either eNOS or CaM protein expression.
Enhanced affinity for Ca 2+ -CaM binding is responsible for constitutive iNOS activity, which depends on the presence of extracellular L-Arg (46). Because we found that BK did not stimulate increased NO in cytokine-treated HLMVEC in the absence of extracellular L-Arg either in the presence (see above) or absence (not shown) of extracellular NO 2 -, we wondered whether increased Ca 2+ -CaM binding would result in enhanced basal L-Arg-dependent eNOS-derived NO, similar to that found with iNOS. To assess this, we depleted control and cytokine-treated HLMVEC of L-Arg and then added back 1 mM LArg to stimulate basal NOS activity (Fig. 6B) . As previously shown (11), L-Arg stimulated basal iNOS-derived NO production in cytokine-treated HLMVEC which was significantly inhibited by the iNOS-selective inhibitor 1400W. However, there remained a substantial NO response that was almost completely inhibited by the further addition of eNOS inhibitor L-NNA (Fig. 6B) . Conversely, in control HLMVEC (which express low levels of iNOS; Fig. 2A ) basal eNOS activity was not detectable as L-Arg stimulated a smaller NO response that was inhibited by iNOS inhibitor 1400W, but not by eNOS inhibitor L-NNA (Fig.  6B) . Thus, eNOS-derived NO can be generated by the addition of extracellular L-Arg and is consistent with our finding of enhanced eNOS binding to Ca 2+ -CaM at basal Ca 2+ levels in cytokine-treated endothelial cells.
Effect of cytokine treatment on B2R and G protein expression -Typically, B2Rs are constitutively expressed whereas B1R expression is induced by inflammatory cytokines (16) . However, IL-1β was reported to induce upregulation of both the B1R and B2R in murine airways (47) . To investigate whether cytokine treatment with IL-1β and IFN-γ increased B2R expression, we measured B1R and B2R mRNA levels in control and cytokine-treated HLMVEC using quantitative real-time RT-PCR. Consistent with our previous studies (21,44), cytokine treatment increased B1R mRNA expression (control cells B1R/GAPDH = 0.72 ± 0.088; cytokine-treated cells B1R/GAPDH = 1.17 ± 0.023; n = 3). However, B2R mRNA did not change after cytokine treatment (control cells B2R/GAPDH = 1.18 ± 0.008; cytokine-treated cells B2R/GAPDH = 1.12 ± 0.005; n = 3). In addition, cytokine treatment did not alter protein expression of Gα q/11 or Gα i1,2 (data not shown).
B2R-mediated NO production is regulated by a MEK1/2 and JNK1/2-dependent pathway in cytokine-treated endothelial cells -We previously
showed that B1R-dependent activation of prolonged NO output via iNOS in cytokine-treated HLMVEC is dependent on activation of the MEK1/2 -ERK1/2 MAP kinase pathway (11) (12) (13) . Because B2R stimulation has been reported to activate ERK (16, 48) , we evaluated the role of this pathway in B2R-mediated NO production in control and cytokine-treated HLMVEC using three structurally distinct MEK1/2 inhibitors: PD98059 (25 μM), U0126 (10 μM) and CI-1040 (2 µM).
As shown in Fig. 7A , all 3 inhibitors significantly reduced B2R-mediated NO production from cytokine-treated HLMVEC, but had little effect in control endothelial cells. The negative control compound, U0124 (10 μM), a structurally similar but inactive analogue of U0126, did not alter B2R-mediated NO production in control or cytokinetreated HLMVEC.
MEK1/2 inhibitors also significantly blocked the prolonged NO production stimulated by BK in cytokine-treated HEK-B2R/eNOS (Fig. 4B) (Fig. 4C) .
MEK1/2 is the dual specificity kinase directly upstream of ERK1/2 activation and blockade of a signal by MEK1/2 inhibition is usually taken as prima facie evidence that the response requires activation of ERK1/2. To determine whether ERK1/2 was involved in the regulation of eNOS, we measured B2R-stimulated NO production in control and cytokine-treated HLMVEC preincubated in the absence or presence of a direct ERK1/2 inhibitor (FR180204; 50 μM) or a structurally similar inactive analogue (FR180289; 50 μM).
Surprisingly, FR180204 did not significantly inhibit B2R-mediated NO production in either control or cytokine-treated HLMVEC compared with cells pretreated with the negative control FR180289 (Fig. 7B) . As a positive control to demonstrate the effectiveness of the ERK1/2 inhibitor in these cells, we measured NO production in cytokine-treated HLMVEC in response to B1R agonist DAKD. We previously showed that B1R stimulation of high output NO results from ERK1/2-dependent phosphorylation of iNOS at Ser 745 leading to its acute activation (11) (12) (13) .
As shown in Fig. 7C , FR180204 effectively attenuated B1R-mediated NO production in cytokine-treated HLMVEC. These data support the conclusion that B2R stimulation activates eNOS via a MEK1/2-dependent but ERK1/2-independent pathway. ERK1/2 is a relatively specific substrate of MEK1/2, but it has been reported that MEK1/2 can also phosphorylate c-Jun-N-terminal kinase (JNK) (49) . To determine whether JNK1/2 was involved in the regulation of eNOS, we utilized two specific JNK1/2 inhibitors; JNK inhibitor II (SP600125; 20 µM) and JNK Inhibitor VIII (10 μM). As shown in Fig. 7D , B2R-mediated NO production was significantly reduced in cytokinetreated HLMVEC pretreated with JNK inhibitor II or JNK Inhibitor VIII. Furthermore, knockdown of JNK1/2 expression by electroporating HLMVEC with JNK1/2 siRNA significantly reduced B2R-mediated NO production in cytokine-treated endothelial cells (Fig. 7E) . In contrast, JNK1/2 siRNA had no significant effect on B2R-mediated NO production in control HLMVEC (Fig. 7F) .
To determine the effect of cytokine treatment on B2R-mediated JNK1/2 activation in HLMVEC, we measured the time course of JNK1/2 phosphorylation in response to BK. We found that JNK1/2 phosphorylation increased at 1 min, reaching a maximum 3.3 -fold increase at 5 min and slowly decreasing thereafter, but still remaining elevated over basal at 30 and 60 min (Fig. 8A ). In contrast, there was minimal change in JNK1/2 phosphorylation in response to BK in control HLMVEC (Fig. 8A) . The activation of JNK1/2 in cytokine-treated HLMVEC required coupling through Gα i/o as it was inhibited in cells pre-incubated with PTx (1.5 μg/ml; 3 h) (Fig. 8B) . Furthermore, as found with the NO response, B2R -mediated JNK1/2 activation in cytokine-treated HLMVEC was blocked by the MEK1/2 inhibitor U0126 (Fig. 8C ) and was also reduced in cells in which MEK1/2 was knocked down with siRNA (Fig. 8D) .
Because the B2R can transactivate the epidermal growth factor receptor (EGFR) (48,50), we measured NO production from cytokinetreated HLMVEC pretreated in the absence or presence of the EGFR tyrosine kinase inhibitor PD153035 (200 nM; 30 min) prior to stimulation with BK. B2R-mediated NO production was not altered by the EGFR tyrosine kinase inhibitor (data not shown). The concentration of PD153035 used was effective, as it inhibited EGF-mediated eNOS-dependent NO production and JNK phosphorylation in cytokine-treated HLMVEC (data not shown).
Overall, these data show that under inflammatory conditions, B2R stimulation induces eNOS activation and prolonged NO output by a Gα i/o -mediated, MEK1/2 and JNK1/2-dependent pathway in HLMVEC. 7D) . Conversely, phosphorylation of these residues in response to BK was essentially abolished in the presence of BAPTA-AM (Fig. 9C and 9D) , which had no effect on prolonged NO production (Fig. 5A) .
B2R-mediated eNOS phosphorylation at
Bradykinin has divergent effects on endothelial wound healing in control and cytokine-treated endothelial cells -Endothelial NO production is known to regulate wound healing and angiogenesis (53, 54) . To determine if B2R-mediated NO production affects endothelial cell migration, we utilized the in vitro scratch assay (Fig. 10) and a modified Boyden Chamber assay (Fig. 11) . Stimulation of control HLMVEC with BK significantly improved wound healing and increased their transmigration (Figs. 10 & 11) . However, BK stimulation of cytokine-treated HLMVEC delayed wound healing and reduced transmigration of cells (Figs. 10 & 11) . Furthermore, the changes in wound healing and transmigration in response to BK were mediated by B2R activation and were eNOS-dependent as both the stimulatory response in control cells and the inhibitory response in cytokine-treated cells were blocked by B2R antagonist HOE-140 or eNOS inhibitor L-NNA. As a reduction in wound healing can also be caused by increased apoptosis, we utilized fluorescein-dUTP to label DNA at strand breaks as a marker of apoptosis. We found that B2R-mediated eNOS activation in cytokinetreated HLMVEC did not induce endothelial cell apoptosis (Fig. 10C) .
NO itself enhances wound healing and angiogenesis (55) , but enhanced levels of oxidative and nitroxidative stress can alter the progression of wound healing (54) . To determine whether the presence of reactive oxygen species (ROS) reduces B2R-mediated NO bioavailability, we pre-incubated control and cytokine-treated HLMVEC without or with the superoxide scavengers tempol (10 μM) or polyethylene glycol-superoxide dismutase (PEG-SOD; 100 U/ml), 30 min prior to stimulation with 1 μM BK. We found that B2R-mediated NO production was increased by ~30% in the presence of tempol ( Fig.  12A ; middle) or PEG-SOD (Fig. 12B ) in cytokinetreated HLMVEC but had no effect in control cells ( Fig. 12A; left) . Moreover, the reduction in wound healing mediated by B2R stimulation in cytokine-treated HLMVEC was inhibited in the presence of tempol (Fig. 12C & 12D) . Overall, these data suggest that the presence of superoxide in inflamed endothelium reduces B2R-mediated NO bioavailability and explains part of the reduction in endothelial cell migration.
These data indicate that superoxide is generated in cytokine-treated cells and can reduce the NO detected by the microsensor. Although these results would argue against the likelihood that BK stimulation reduces superoxide-mediate consumption of NO, we assessed the maximal increase in basal NO that could be achieved by scavenging superoxide.
In cytokine-treated HLMVEC (pre-treated with 1400W to block iNOS activity), addition of 100 µM tempol generated only a small increase in detectable basal NO that returned to baseline before 20 min (Fig. 12A, right  panel) . These results are consistent with our finding that eNOS is basally active in cytokinetreated endothelial cells (Fig. 6B) , some of which is consumed by superoxide, and that the prolonged increase in NO after B2R stimulation does not arise from blocking the consumption of basally generated NO, but rather an increase in eNOSderived NO production.
DISCUSSION
iNOS is considered to be the primary source of "high output" NO in inflammation (3, 19, 56) . This view arose from work done in rodent cells, where iNOS expression can be induced to high levels and from the fact that iNOS has basal activity that is not dependent on increased [Ca 2+ ] i (3, 19, 56) . Our study challenges this notion, as we find that eNOS can generate "high output" NO in human endothelium under inflammatory conditions. We found a similar response in cytokine-treated HEK cells co-transfected with eNOS and B2R. Furthermore, this response is "iNOS-like" in that eNOS has higher basal affinity for Ca 2+ -CaM which is reflected in a higher constitutive activity and lack of a requirement for an increase in [Ca 2+ ] i for agonist-stimulated activity (Fig. 13A) .
Instead, B2R-dependent eNOS activation is mediated by a novel Gα i/o -and MEK1/2 JNK1/2-dependent pathway in cytokine-treated HLMVEC (Fig. 13B) . The ability to generate high output eNOS-derived NO is likely more relevant in humans than in rodents because iNOS expression is highly induced in rodent cells in response to LPS or cytokines but in human cells, iNOS expression is much lower and in many cases difficult to detect (3,57) due to epigenetic silencing (58) . As a result, basal iNOSderived NO is much lower in human than in rodent cells, and high output eNOS-derived NO has the potential to play a more important role in human tissues.
Electrode-based measurements of NO have the advantage of detecting real time output of authentic NO with high sensitivity. However, as this method measures changes in NO concentration, it would not distinguish between a B2R and eNOS-dependent reduction in consumption of basally generated NO and increased NO production by eNOS. Cellular NO has a relatively short half-life (< 2 sec) as it is rapidly consumed by heme-containing molecules, oxidation, nitration, nitrosation, peroxidases as well as other mechanisms, some still undefined (38,59).
A major pathway for cellular consumption of NO, especially under inflammatory conditions, is the extremely rapid rate of reaction with superoxide (38,59,60) and it has been concluded that only reactions as fast as this can effectively compete with rapid NO diffusion out of the cell (59) (where it would be detected by the electrode), thereby eliminating many known pathways.
If B2R activation stimulates an increase in NO by decreasing superoxide production, we would expect the superoxide scavenger tempol to generate a similar response, which it did not. These data do not rule out BK-mediated inhibition of other, possibly unknown, mechanisms of NO consumption. Therefore, we used a well-established approach (37,61) to "clamp" cellular NO concentrations with the long half-life NO donor DETA-NONOate and found that BK had no effect on the NO consumption rate in cytokine-treated HLMVEC. One other mechanism by which B2R activation might increase eNOS-dependent NO is by enhancing reduction of NO 2 -to NO. Although we showed that the NO response is eNOS-dependent, it has been reported that eNOS can act as a nitrite reductase (39) . However, this is unlikely as the reported nitrite reductase activity of eNOS is present only under hypoxic and/or acidic conditions and is inhibited with 300 µM L-Arg (39) (our medium contains 400 µM L-Arg). Indeed, stimulation of cytokine-treated HLVMEC with BK in L-Arg-free medium in the presence of 10 µM NO 2 -[which yields maximal eNOSmediated nitrite reductase activity(39)] did not generate any NO.
Finally, total NO 2 -/ NO 3 -accumulation was significantly increased after BK stimulation in cytokine-treated HEK-B2R/eNOS cells, but was undetectable after stimulation of control HEK-B2R/eNOS cells. Taken together, our evidence supports the conclusion that the prolonged NO output generated by B2R activation in cytokine-treated HLMVEC results from activation of eNOS. We found that B2R-mediated eNOS activation was independent of increased [Ca 2+ ] i . Although Ca 2+ -CaM binding is required for the activity of all three NOS isoforms, the "calcium-independence" of iNOS is due to its high affinity for Ca 2+ -CaM, which does not dissociate at normal low concentrations of [Ca 2+ ] i (62) . Interestingly, we found a ~4-fold increase in the level Ca 2+ -CaM pulled down with eNOS isolated from cytokinetreated HLMVEC compared with control cells. Consistent with this, we also found that L-Arg stimulates significant basal eNOS-dependent NO production in cytokine-treated HLMVEC, but not in control cells. This may also serve as a "priming" mechanism, rendering eNOS more susceptible to prolonged activation in response to B2R stimulation. Although (68, 69) . The B2R is classified as a prototypical Gα q/11 -coupled receptor but can also couple to Gα i/o (16) . We found that B2R-mediated JNK1/2 phosphorylation and NO production were PTx-sensitive, showing that JNK1/2 is activated downstream of B2Rs coupled to Gα i/o , consistent previous reports that Gα i/o and associated Gβγ-subunits can activate JNK (69) (70) (71) . Surprisingly, we found Gα i/odependent JNK phosphorylation to be downstream of MEK1/2, although Gα i/o -dependent JNK activation has been reported to be independent of MKK4/7 (70) and one report showed MEK1/2 to phosphorylate JNK in a human astrocyte (U-251) cell line (49) .
JNKs are proline-directed Ser/Thr kinases that phosphorylate many nuclear and cytosolic substrates (72) . Human eNOS contains 15 Ser/Thr residues that are potential JNK phosphorylation sites as determined using ExPASy ScanProsite. However, JNK often utilizes a docking domain (R/K 2-3 -X 1-6 -L/I-X-L/I ) on the substrate or on a scaffold protein that facilitates JNK interaction with substrates lacking a JNK binding domain (JBD) (72, 73) , which confers enhanced specificity of phosphorylation. Although human eNOS does not contain a typical JBD, JNK might interact with a novel JBD in eNOS or with a scaffold protein containing a JBD to facilitate eNOS phosphorylation. JNK has not been linked to eNOS activation, but was recently reported to basally phosphorylate eNOS at Ser 116 (bovine numbering) to reduce eNOS-derived NO in bovine aortic endothelial cells (52) . In contrast, we found that B2R-mediated JNK activation was required for stimulation of prolonged eNOS activity, which was independent of phosphorylation at the wellknown regulatory sites. These data suggest that JNK controls eNOS activation by a different mechanism, possibly via phosphorylation at a novel regulatory site. Alternatively, JNK may activate another kinase that phosphorylates eNOS (Fig. 13B) or the activation process may be independent of eNOS phosphorylation, for example by altering protein interactions with eNOS or eNOS localization (23,74).
Enhanced B2R-mediated signaling and eNOSdependent NO output after cytokine treatment could be facilitated by mechanisms in addition to increased Ca 2+ -CaM binding. Cytokines alter cell functions by promoting significant changes in gene expression and protein synthesis (43) . Although cytokine treatment did not alter B2R mRNA levels or the protein expression of Gα q/11 , Gα i1,2 , eNOS or JNK, B2R-mediated JNK activation was more robust in cytokine-treated HLMVEC. However, cytokine treatment might alter the membrane microdomain localization of signaling components without altering their overall expression. For example, Gα q/11 binds caveolin to concentrate in caveolae, whereas Gα i/o targets lipid rafts by default (75) . B2Rs and eNOS localize to caveolae in healthy endothelial cells (76) , but inflammation can induce changes in membrane phospholipid composition that affects cholesterol-rich microdomains to alter signal transduction (77) .
Thus, it is possible that cytokine treatment promotes segregation of B2Rs into lipid raft microdomains, enhancing its Gα i/odependent signaling and eNOS activation. Cytokine treatment could also alter posttranslational modifications of the B2R that might facilitate Gα i/o coupling. Alternatively, it may not be B2R-Gα i/o coupling that is enhanced by cytokines, but downstream components. For example, MAP kinases rely on scaffolding proteins to amplify and modulate the specificity of their responses (72, 73) . Thus, cytokine treatment might induce the expression of a scaffold protein or facilitate its binding to MEK1/2, JNK1/2 and eNOS to allow efficient activation to occur. Interestingly, although cytokine treatment enhanced signaling via Gα i/o and JNK, Ca 2+ signaling through Gα q/11 was also increased, indicating a major switch of B2R coupling from Gα q/11 to Gα i/o is likely not the primary mechanism.
Endothelial-derived NO and its derivatives play critical roles in regulating normal vascular functions, but can also be involved in exacerbating or ameliorating cardiovascular diseases (8, 10, 56, 60) .
For example, NO is a major regulator of angiogenesis and plays important roles in wound healing (53) . We found that B2R-mediated eNOS-derived NO has opposing effects on endothelial cell migration in control and cytokine-treated HLMVEC, promoting migration in control cells but inhibiting migration in cytokine-treated endothelial cells.
Thus, prolonged B2R-mediated NO production might reduce angiogenesis as it was recently shown that caveolin1-deficient mice have impaired angiogenesis which is partially mediated by increased eNOS activation (78) . The mechanism by which NO regulates endothelial cell migration is not understood, but VEGF-induced angiogenesis is dependent on NO production and subsequent increased cGMP and PKG activation, resulting in phosphorylation and activation of p38 and ERK1/2 (79) . While NO clearly plays a pro-migratory role, the balance between the concentration of NO and level of oxidative and nitroxidative stress can differentially regulate its effect on the endothelium (54) . For example, although NO itself is promigratory, under inflammatory conditions, combined with superoxide to generate ONOO -, it could inhibit migration (54) . This is consistent with our finding that scavenging of superoxide with tempol or PEG-SOD enhanced the NO detected in response to BK in cytokine-treated HLMVEC and reduced the inhibition of cell migration. However, it is interesting that in the presence of tempol, BK did not stimulate cell migration it did in control HLMVEC. This could be due to the higher and more prolonged output of NO generated under inflammatory conditions. HLMVEC in the lung circulation form the essential semi-permeable barrier that dynamically regulates the passage of fluid and protein (80) . Sepsis is a leading cause of acute lung injury characterized by inflammation and increased lung microvascular endothelial permeability.
The precise role of NO in sepsis and lung inflammation is still controversial. Studies have shown that NO production may have both salutary and harmful effects. A general theme is that low output NO promotes barrier function whereas high output NO, especially when combined with oxidants, is damaging and increases permeability (9, 14, 81, 82) . For example, caveolin-1 depletion results in microvascular hyperpermeability, which may be due to increased eNOS-derived NO (82, 83) , whereas decreased NO production caused by eNOS gene deletion or NOS inhibition also increased vascular permeability (84) . Thus, a proper range of NO concentration is crucial in maintaining endothelial barrier function. NO regulates vascular permeability via activation of guanylate cyclase (85) or nitrosylation of cysteine residues on critical signaling molecules. For example, VEGF-mediated eNOS activation induces nitrosylation of β -catenin, thereby disrupting its association with VE-cadherin and increasing endothelial permeability via the paracellular pathway (86) . VEGF also enhances endothelial permeability by stimulating β-catenin endocytosis that is dependent on β-arrestin 2 (87) and S-nitrosylation of β-arrestin 2 promotes its binding to clathrin heavy chain/beta-adaptin, thereby inducing endocytosis (88) .
Under inflammatory conditions, ONOO -generation becomes an important mediator of enhanced endothelial permeability. ONOO -, via Tyr nitration, activates protein phosphatase 2A (89) or inactivates actin (90) or p190RhoGAP-A (91) and as an oxidant it activates tyrosine kinases such as Src or inactivates phosphatases such as PTP1B (60), all of which can disrupt the endothelial barrier.
Overall, the findings of this study blur the traditional distinctions between the functions of eNOS and iNOS in generating NO in inflammation. Furthermore, our previous studies have challenged the view that iNOS is only regulated at the level of expression or substrate supply, functioning as a constitutively active, uncontrolled generator of NO (1, 3, 56) . That is, the control of iNOS activity is more complex and "eNOS-like" than previously recognized. We found that stimulation of the kinin B1R in cytokine-treated HLMVEC or transfected HEK cells results in signaling through a Gα i/o -, βγ-and β-arrestin 2-dependent pathway activating Src Ras Raf MEK1/2 ERK1/2 (11-13). ERK1/2 in turn phosphorylates iNOS at Ser 745 , leading to a 3-to 5-fold increase in iNOS activity over basal (11) . The presence of both eNOS and iNOS-dependent high output NO pathways in inflamed endothelium could have important consequences in regulating endothelial function and a better understanding of their roles could lead to new therapeutic approaches to ameliorate endothelial dysfunction caused by overproduction of NO in inflammatory vascular or lung disease. 
FIGURE 13.
Proposed signaling pathway for basal and BK-mediated eNOS activation in inflamed endothelium. A. In healthy ('control') endothelial cells, eNOS is inactive and does not interact with calmodulin (CaM) at resting Ca 2+ levels. Conversely, eNOS associates with CaM at resting Ca 2+ levels in HLMVEC pretreated with IL-1β and IFN-γ ("cytokine treated") for 16-24 h. Consequently, L-Arg stimulated eNOS activation is enhanced in cytokine treated but not control cells. B. In cytokine-treated HLMVEC, prolonged B2R-dependent NO production is mediated by PTx-sensitive Gα i/o , MEK1/2-dependent JNK1/2 activation. The mechanism by which JNK1/2 regulates eNOS activation has yet to be determined, but might involve JNK1/2-dependent phosphorylation of eNOS in a region that facilitates Ca 2+ -CaM binding, thereby reducing its dependence on increases in [Ca 2+ ] i . B2R-mediated NO production inhibits migration of cytokine-treated HLMVEC, which was partially reversed in the presence of the ROS scavenger tempol. Impaired cell migration could prevent proper angiogenesis and wound healing. 
